Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab plus XELOX in First-Line Metastatic Colorectal Cancer
NCT00215722Phase 2Unknown
- Sponsor
- Grupo de Investigação do Cancro Digestivo
- Start
- Jul 2005
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in metastatic colorectal cancer (mCRC), sponsored by Grupo de Investigação do Cancro Digestivo. Status: unknown.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00215722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00215722.